CCEL vs RARE · P/E 490, rev $15.5M vs rev $350.0M
CryoCell International Inc (CCEL) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
CryoCell International Inc (CCEL) is a medical care facilities company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported CCEL revenue for 2026-05-31 was $15.5M. Net income was $601.7K. CCEL currently screens at market cap $39.6M and trailing P/E 490.0.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
CCEL currently screens at market cap $39.6M and trailing P/E 490.0. RARE currently screens at market cap $2.79B.
Not investment advice. Open the CCEL and RARE stock pages for the full models.
Not investment advice.